According to informed sources, the United States is developing regulations governing pharmaceutical companies' investments in China, which could preserve their ability to secure the majority of licensing deals for drugs developed in China. This approach would differ from the Trump administration’s tightening of business ties with China across other sectors under new national security legislation, and would be more lenient than restrictions sought by some members of Congress. The rules, drafted by the U.S. Department of the Treasury, may allow American pharmaceutical firms to invest in promising new drugs being developed by Chinese companies—as long as those drugs are unrelated to pathogens or biotechnologies that could potentially be weaponized. The regulations remain subject to change and have not yet been finalized, particularly if Donald Trump re-enters the political arena.
Image source: internet
Original article: toutiao.com/article/1876740041832459/
Disclaimer: The views expressed in this article are those of the author alone.